(Q36620845)

English

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

scientific article published on January 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

author name string

H Kunisue

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J Kurebayashi

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

T Otsuki

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

C K Tang

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Kurosumi

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S Yamamoto

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

K Tanaka

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H Doihara

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

N Shimizu

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H Sonoo

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 January 2000

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

82

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

46-51

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

https://scigraph.springernature.com/pub.10.1054/bjoc.1999.0875

0 references

Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Human myeloma cell apoptosis induced by interferon-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

The neu (c-erbB-2) oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

30 September 2017

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

28 June 2018

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

28 June 2018

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

28 June 2018

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

28 June 2018

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

28 June 2018

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

20 September 2018

Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363211

4 December 2018

Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of bcl-2 and apoptotic DNA fragmentation in human endometrial adenocarcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.1999.0875

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36620845&oldid=1609217463"